Kestra Medical Technologies filings document the public-company disclosures of a Bermuda-incorporated medical technology issuer listed on Nasdaq under KMTS. Its Form 8-K reports have furnished quarterly and annual financial results, revenue guidance, and Regulation FD disclosures tied to the ASSURE WCD and ACE-PAS post-approval study results.
The company’s proxy materials and annual meeting filings cover board elections, independent auditor ratification, shareholder voting results, and equity compensation matters, including the 2025 Employee Stock Purchase Plan. These records also identify governance procedures and formal shareholder actions for the wearable defibrillator and digital health business.
Kestra Medical Technologies, Ltd. will hold its 2026 Annual General Meeting on September 9, 2026 at 9:00 a.m. Eastern Time, conducted as a virtual-only webcast at www.virtualshareholdermeeting.com/KMTS2026. Shareholders of record at the close of business on July 17, 2026 may attend and vote.
Shareholders are asked to elect three Class II directors (Traci S. Umberger, Raymond W. Cohen, and Kevin Reilly) to terms ending in 2029 and to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending April 30, 2027. The proxy materials outline a classified eight‑member board, committee structures, related‑party transactions, and detailed 2026 executive pay, including $7,501,904 in total compensation for CEO Brian Webster. Kestra is an emerging growth company, so no advisory vote on executive compensation is included.
Kestra Medical Technologies, Ltd. executive Timothy P. Moran, Chief Business Officer, reported an acquisition of 39,113 common shares. These shares were earned from a July 17, 2025 grant of performance-based RSUs ("PSUs") that vested 100% on July 15, 2026 after specified performance goals were achieved. The PSUs settled at a reported price of $0.0000 per share, increasing Moran’s direct holdings to 81,601 common shares. The transaction was coded as a grant/award acquisition, not a market purchase or sale, and was not indicated as being under a Rule 10b5-1 trading plan.
Kestra Medical Technologies Chief Commercial Officer Alfred J. Ford Jr. acquired 58,832 Common Shares on July 15, 2026 at $0.00 per share. The shares were earned from performance-based RSUs granted July 17, 2025, which vested 100%, bringing his direct holdings to 133,471 shares.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem acquired 44,118 Common Shares on July 15, 2026, at 0.0000 per share, upon vesting of performance-based RSUs granted on July 17, 2025 after achievement of specified goals. Following this award, he directly owns 112,079 Common Shares.
Kestra Medical Technologies, Ltd. reported that director and General Counsel Traci S. Umberger acquired 58,832 Common Shares on July 15, 2026 at $0.00 per share, reflecting the vesting of performance-based RSUs (PSUs) granted on July 17, 2025. After this award, Umberger directly holds 221,634 Common Shares.
Kestra Medical Technologies President and CEO Brian Daniel Webster reported several Common Share transactions dated July 15, 2026. He acquired 176,470 shares at $0.0000 per share upon full vesting of performance-based RSUs granted in 2025, then sold a total of 15,000 shares at weighted-average prices of $22.0105, $22.6333 and $23.9983, with underlying trade prices ranging from $21.45 to $24.10, under a Rule 10b5-1 trading plan adopted September 29, 2025. Following these transactions, he directly owned 556,937 Common Shares.
A notice by Brian Webster covers 15,000 shares of Kestra Medical Technologies, Ltd. common stock for potential sale, with a value of 336,609.41. Merrill Lynch, 225 Liberty St Floor 37, New York, NY 10281, and Nasdaq are listed in connection with this transaction. The shares were acquired on 01/01/2026 via a restricted share issuance granted as part of the issuer’s equity compensation plan.
The disclosure also lists three prior sales of 15,000 common shares each on 04/15/2026, 05/15/2026 and 06/15/2026, with reported values of 300,671.04, 314,329.85 and 312,142.94, respectively.
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital health company focused on cardiac recovery. Its Cardiac Recovery System platform is anchored by the ASSURE wearable cardioverter defibrillator, which has protected nearly 40,000 patients as of April 30, 2026.
The ASSURE system emphasizes patient comfort and compliance via SensorFit garments and high-fidelity ECG, achieving median wear of more than 23 hours per day. In the 21,612‑patient ACE-PAS study, ASSURE showed a 100% conversion rate for VT/VF events and low false alarms, with a software update targeting further reductions.
Kestra estimates a WCD addressable market of about $10 billion in the U.S. and $14 billion internationally, versus 2025 global WCD revenues of $1.1 billion and only 16% penetration of eligible U.S. patients. Revenue comes primarily from leasing ASSURE as Durable Medical Equipment, supported by Medicare and contracts covering over 290 million U.S. lives. Key risks include a history of net losses, dependence on ASSURE WCD, reliance on limited suppliers, extensive healthcare and fraud‑and‑abuse regulation, identified material weaknesses in internal control over financial reporting, and significant influence from Bain Capital.
Kestra Medical Technologies, Ltd. entered into a five-year senior secured term loan facility of up to $200.0 million with funds managed by Pharmakon Advisors. Tranche A of $75.0 million funded on July 10, 2026, generating approximately $20.0 million of net proceeds after fees and full repayment of the prior Perceptive Credit loan, which was terminated and its security interests released.
The Term Loans mature on July 10, 2031, bear interest at three-month SOFR + 5.50% with a 3.25% SOFR floor, include 48 months of interest-only payments, and then amortize quarterly from the second fiscal quarter of 2030. Covenants include minimum liquidity of at least $20.0 million, limits on additional indebtedness, liens, dividends and mergers, and a security interest over substantially all assets, including intellectual property.
For the quarter ended April 30, 2026, revenue was $28.6 million, up 66% year over year, with gross margin of 54.8%. Fiscal 2026 revenue was $95.1 million, up 59%, with gross margin of 51.4%. GAAP net loss was $131.6 million and adjusted EBITDA loss was $87.0 million. Cash, cash equivalents and investments totaled $262.2 million as of April 30, 2026. The company guides to FY27 revenue of $137 million, implying 44% growth versus FY26.
Kestra Medical Technologies Chief Business Officer Timothy P. Moran acquired additional company stock through an employee purchase plan. He obtained 227 shares of common stock on June 30, 2026 at $21.55 per share under the 2025 Employee Stock Purchase Plan for the January 1–June 30, 2026 period. Following this ESPP purchase, he directly holds 42,488 shares of Kestra Medical Technologies common stock, which the disclosure states includes unvested restricted stock units.